Friday 6 November 2026 Export AXSM’s income statement to Excel — free account

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.

Revenue: +51.9%
EPS: +73.9%
Free cash flow: −1,078.3%
Total debt: +4.04%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

132.13 2.33 +1.80%

Follow AXSM

Alert me

Market cap: $6.8B
P/E: 0.0×
Fwd P/E: −49.2×
Dividend yield: —
F-score: 5/9
Altman Z: 6.91
Beneish M: −2.53
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Axsome Therapeutics, Inc. (AXSM) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Axsome Therapeutics, Inc. (AXSM) trades at a P/S ratio of 7.8×. Over the past ten years it has ranged from 0.0× (March 2023) to 27.2× (June 2023); the current reading is higher than 67% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/AXSM/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Axsome Therapeutics, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/AXSM/metrics/ps-ratio">Axsome Therapeutics, Inc. (AXSM) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	14.2×	35.38%
FY2024	10.5×	(18.75%)
FY2023	12.9×	—
FY2022	0.0×	—

Period	P/S ratio	Change
Sep 2026	11.2×	(31.55%)
Jun 2026	16.3×	33.63%
Mar 2026	12.2×	(14.14%)
Dec 2025	14.2×	31.47%
14 more quarters	Free account

Against its own ten years

Low 0.0× High 27.2×

Ten-year median 0.0×

Current reading's percentile 0

Company	P/S ratio
BLTE Belite Bio, Inc. Sponsored ADR compare	n/m
ABVX Abivax SA Sponsored ADR compare	n/m
ORKA Oruka Therapeutics, Inc. compare	n/m
IONS Ionis Pharmaceuticals, Inc. compare	7.4×
AXSM Axsome Therapeutics, Inc.	7.8×
MIRM Mirum Pharmaceuticals, Inc. compare	9.2×
LGND Ligand Pharmaceuticals Incorporated compare	23.6×
RYTM Rhythm Pharmaceuticals, Inc. compare	25.5×
PRAX Praxis Precision Medicines, Inc. compare	901×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Axsome Therapeutics, Inc. (AXSM) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on AXSM

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on AXSM

Stockrow Weekly